




**Figure S1.** Recurrence patterns for acral and cutaneous melanoma patients.




**Figure S2.** Kaplan-Meier curves of RFS (A) and DMFS (B) for all enrolled acral and cutaneous patients stratified by adjuvant PD-1 inhibitor treatment versus conventional IFN treatment or observation.




**Figure S3.** OS among all enrolled acral and cutaneous melanoma patients stratified by adjuvant PD-1 inhibitor treatment versus conventional IFN or observation, with a p-value of 0.019 between the PD-1 and the IFN groups.




**Figure S4.** RFS for all stage IIIC and IIID melanoma patients stratified by adjuvant PD-1 inhibitor treatment versus conventional IFN or observation, with a p-value of 0.003 between the PD-1 and the IFN groups.



**Figure S5.** RFS for all acral melanoma patients stratified by adjuvant PD-1 inhibitor treatment versus conventional IFN or observation, with a p-value of 0.075 between the PD-1 and the IFN groups.



**Figure S6.** RFS for all enrolled patients with ulceration stratified by adjuvant PD-1 inhibitor treatment versus conventional IFN or observation, with a p-value of 0.056 between the PD-1 and the IFN groups.



**Figure S7.** RFS for all melanoma patients with macrometastatic lymph nodes stratified by adjuvant PD-1 inhibitor treatment versus conventional IFN or observation, with a p-value of 0.075 between the PD-1 and the IFN groups.

**Table S1.** RFS of enrolled patients treated with the adjuvant PD-1 inhibitor versus conventional IFN or observation.

	mFP	mRFS	1-yr RFS	2-yr RFS	P value (vs PD-1)
PD-1	21	23	70.0%	49.4%	
IFN	24	15	59.2%	35.1%	0.170
OBS	49	11	45.3%	37.4%	<b>0.036</b>
IFN+OBS	46	13	51.8%	35.1%	<b>0.027</b>

**Table S2.** DMFS of enrolled patients treated with the adjuvant PD-1 inhibitor versus conventional IFN or observation.

	mFP	mDMFS	1-yr DMFS	2-yr DMFS	P value (vs PD-1)
PD-1	21	NR	84.7%	69.4%	
IFN	24	72	85.3%	68.5%	0.106
OBS	49	20	58.6%	48.4%	<b>0.014</b>
IFN+OBS	46	33	70.5%	57.3%	0.087